Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

AstraZeneca pays $560mm, plus potential $590mm in earn-outs, to buy Pearl Therapeutics

Executive Summary

AstraZeneca PLC has paid $560mm up front to buy privately owned Pearl Therapeutics Inc., a company developing inhaled treatments for respiratory diseases. AZ could also pay up to $450mm in development and regulatory earn-outs, plus up to $140mm if specified cumulative sales thresholds are exceeded.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash

Related Companies

UsernamePublicRestriction

Register